




RealRate

PHARMACEUTICAL 2023

Unity Biotechnology Inc
Rank 269 of 471

UNITY
BIOTECHNOLOGY



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Unity Biotechnology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Unity Biotechnology Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 226%, being 19% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	96,535
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,620
Liabilities, Non-Current	37,882
Other Assets	19,990
Other Compr. Net Income	-207
Other Expenses	3,558
Other Liabilities	0
Other Net Income	1,203
Other Revenues	236
Property and Equipment	7,825
Research and Development	36,859
Selling, General and Administrative Expense	20,949

Output Variable	Value in 1000 USD
Assets	124,350
Liabilities	57,502
Expenses	61,366
Revenues	236
Stockholders Equity	66,848
Net Income	-59,927
Comprehensive Net Income	-60,030
BaseVar	122,432
ECR before LimitedLiability	94%
Economic Capital Ratio	226%